ADMA Biologics (ADMA) Financials

$20.44 +0.25 (+1.24%)

As of 05/20/2025 04:00 PM Eastern

Annual Income Statements for ADMA Biologics

This table shows ADMA Biologics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	198	-28	-66	-72	-76	-48	-66	-44	-20	-18
Consolidated Net Income / (Loss)	198	-28	-66	-72	-76	-48	-66	-44	-20	-18
Net Income / (Loss) Continuing Operations	198	-28	-66	-72	-76	-48	-66	-44	-20	-18
Total Pre-Tax Income	126	-28	-66	-72	-76	-48	-66	-44	-20	-18
Total Operating Income	139	22	-39	-58	-65	-41	-60	-39	-17	-16
Total Gross Profit	220	89	35	1.17	-19	-10	-25	-6.40	4.30	2.87
Total Revenue	426	258	154	81	42	29	17	23	11	7.18
Operating Revenue	426	258	154	81	42	29	17	23	11	7.18
Total Cost of Revenue	207	169	119	80	61	40	42	29	6.36	4.31
Operating Cost of Revenue	207	169	119	80	61	40	42	29	6.36	4.31
Total Operating Expenses	81	67	75	60	46	31	35	33	22	18
Selling, General & Admin Expense	78	63	70	55	39	28	30	25	14	11
Research & Development Expense	1.81	3.30	3.61	3.65	5.91	2.34	3.93	5.57	7.69	7.02
Amortization Expense	0.39	0.72	0.72	0.72	0.72	0.84	0.84	1.23	0.00	-
Total Other Income / (Expense), net	-13	-50	-27	-13	-11	-6.85	-5.45	-4.45	-2.18	-2.46
Interest Expense	15	51	26	13	11	19	5.52	4.50	2.24	2.56
Interest & Investment Income	2.10	1.62	0.05	0.04	0.29	0.80	0.20	0.06	0.05	0.04
Other Income / (Expense), net	-0.19	-0.29	-0.64	-0.25	-0.13	11	-0.13	-0.01	0.00	0.07
Income Tax Expense	-72	0.00	0.00	-	-	-	-	-	-	-
Basic Earnings per Share	$0.85	($0.13)	($0.33)	($0.51)	($0.88)	($0.89)	($1.45)	($1.91)	($1.61)	($1.73)
Weighted Average Basic Shares Outstanding	233.08M	223.98M	197.87M	139.58M	86.15M	54.35M	45.19M	22.90M	12.15M	10.41M
Diluted Earnings per Share	$0.81	($0.13)	($0.33)	($0.51)	($0.88)	($0.89)	($1.45)	($1.91)	($1.61)	($1.73)
Weighted Average Diluted Shares Outstanding	243.34M	223.98M	197.87M	139.58M	86.15M	54.35M	45.19M	22.90M	12.15M	10.41M
Weighted Average Basic & Diluted Shares Outstanding	237.62M	228.22M	222.16M	195.92M	86.15M	54.35M	45.19M	22.90M	12.15M	10.41M

This table shows ADMA Biologics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	27	112	36	32	18	-18	2.57	-6.37	-6.79	-12	-15
Consolidated Net Income / (Loss)	27	112	36	32	18	-18	2.57	-6.37	-6.79	-12	-15
Net Income / (Loss) Continuing Operations	27	112	36	32	18	-18	2.57	-6.37	-6.79	-12	-15
Total Pre-Tax Income	33	35	37	36	18	-18	2.57	-6.37	-6.79	-12	-15
Total Operating Income	35	38	40	39	22	14	8.69	-0.47	-0.81	-6.06	-9.32
Total Gross Profit	61	63	60	57	39	31	25	17	17	14	9.66
Total Revenue	115	118	120	107	82	74	67	60	57	50	41
Operating Revenue	115	118	120	107	82	74	67	60	57	50	41
Total Cost of Revenue	54	54	60	50	43	43	43	43	40	36	31
Operating Cost of Revenue	54	54	60	50	43	43	43	43	40	36	31
Total Operating Expenses	26	25	20	18	17	17	16	17	17	20	19
Selling, General & Admin Expense	25	25	20	18	17	16	15	16	16	19	18
Research & Development Expense	0.83	0.39	0.41	0.56	0.45	0.45	0.60	1.40	0.86	1.07	1.04
Amortization Expense	0.03	0.03	0.03	0.14	0.19	0.19	0.18	0.18	0.18	0.18	0.18
Total Other Income / (Expense), net	-1.43	-3.61	-2.89	-3.35	-3.42	-32	-6.12	-5.90	-5.98	-6.17	-5.58
Interest Expense	1.98	4.12	3.50	3.78	3.77	32	6.40	6.30	6.12	5.74	5.58
Interest & Investment Income	0.61	0.60	0.67	0.45	0.38	0.61	0.42	0.41	0.17	0.00	0.01
Other Income / (Expense), net	-0.06	-0.09	-0.06	-0.02	-0.04	-0.10	-0.15	-0.01	-0.03	-0.44	-0.01
Income Tax Expense	6.55	-77	0.84	3.79	0.60	-	0.00	0.00	0.00	-	-
Basic Earnings per Share	$0.11	$0.48	$0.15	$0.14	$0.08	($0.08)	$0.01	($0.03)	($0.03)	($0.05)	($0.08)
Weighted Average Basic Shares Outstanding	237.78M	233.08M	234.57M	232.42M	228.87M	223.98M	225.28M	222.68M	221.92M	197.87M	196.38M
Diluted Earnings per Share	$0.11	$0.45	$0.15	$0.13	$0.08	($0.08)	$0.01	($0.03)	($0.03)	($0.05)	($0.08)
Weighted Average Diluted Shares Outstanding	244.68M	243.34M	244.80M	242.17M	236.41M	223.98M	233.76M	222.68M	221.92M	197.87M	196.38M

This table details how cash moves in and out of ADMA Biologics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	52	-35	35	-4.83	29	-0.00	-22	39	-0.53	-6.76
Net Cash From Operating Activities	119	8.80	-60	-112	-102	-76	-63	-37	-18	-15
Net Cash From Continuing Operating Activities	119	8.80	-60	-112	-102	9.71	-63	-37	-18	-15
Net Income / (Loss) Continuing Operations	198	-28	-66	-72	-76	-48	-66	-44	-20	-18
Consolidated Net Income / (Loss)	198	-28	-66	-72	-76	-48	-66	-44	-20	-18
Depreciation Expense	8.05	8.33	7.11	5.50	3.94	3.26	3.45	2.69	0.47	0.47
Amortization Expense	0.81	2.45	2.26	1.75	1.64	1.04	0.96	0.64	0.53	0.27
Non-Cash Adjustments To Reconcile Net Income	15	36	15	3.71	1.95	12	2.35	3.44	1.25	2.55
Changes in Operating Assets and Liabilities, net	-103	-10	-18	-52	-34	41	-3.69	-0.28	-1.01	-0.74
Net Cash From Investing Activities	-8.58	-4.98	-14	-14	-13	-3.81	-2.10	15	0.90	-1.74
Net Cash From Continuing Investing Activities	-8.58	-4.98	-14	-14	-13	-3.81	-2.10	15	0.90	-1.74
Purchase of Property, Plant & Equipment	-8.23	-4.77	-14	-14	-13	-3.81	-2.10	-2.68	-0.07	-0.03
Acquisitions	-0.35	-0.21	0.00	0.00	-	-	-	-	0.00	-
Net Cash From Financing Activities	-58	-39	109	121	144	80	43	61	17	10
Net Cash From Continuing Financing Activities	-58	-39	109	121	144	80	43	61	17	10
Repayment of Debt	-60	-172	-105	0.00	-15	-32	0.00	-22	-0.06	-16
Issuance of Debt	0.00	135	152	0.00	28	73	0.04	45	4.00	-
Issuance of Common Equity	0.00	0.00	65	121	131	48	43	39	13	10
Other Financing Activities, net	2.15	-1.91	-2.76	-0.10	-0.02	-9.21	0.01	-1.78	0.00	16

This table details how cash moves in and out of ADMA Biologics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-32	16	-1.54	43	-6.03	-23	12	-6.69	-17	52	-18
Net Cash From Operating Activities	-20	50	25	46	-2.22	18	12	-6.06	-15	-7.38	-13
Net Cash From Continuing Operating Activities	-20	50	25	46	-2.22	18	12	-6.06	-15	-7.38	-13
Net Income / (Loss) Continuing Operations	27	112	36	32	18	-18	2.57	-6.37	-6.79	-12	-15
Consolidated Net Income / (Loss)	27	112	36	32	18	-18	2.57	-6.37	-6.79	-12	-15
Depreciation Expense	1.97	1.94	1.94	2.05	2.11	2.11	2.09	2.10	2.03	1.94	1.86
Amortization Expense	0.15	0.18	0.22	0.19	0.22	0.66	0.69	0.65	0.45	0.46	0.95
Non-Cash Adjustments To Reconcile Net Income	4.62	6.75	3.19	2.86	2.16	29	2.78	2.62	2.11	2.46	2.30
Changes in Operating Assets and Liabilities, net	-53	-71	-16	8.48	-25	3.60	3.86	-5.06	-13	-0.00	-3.49
Net Cash From Investing Activities	-4.72	-2.75	-1.10	-2.37	-2.36	-1.41	-0.76	-0.87	-1.95	-3.75	-3.38
Net Cash From Continuing Investing Activities	-4.72	-2.75	-1.10	-2.37	-2.36	-1.41	-0.76	-0.87	-1.95	-3.75	-3.38
Purchase of Property, Plant & Equipment	-4.70	-2.76	-1.06	-2.07	-2.35	-1.20	-0.76	-0.87	-1.95	-3.75	-3.38
Acquisitions	-0.02	0.01	-0.04	-0.30	-0.02	-0.21	-	-	0.00	-	-
Net Cash From Financing Activities	-7.13	-31	-25	-0.36	-1.45	-39	0.42	0.24	-0.65	63	-0.84
Net Cash From Continuing Financing Activities	-7.13	-31	-25	-0.36	-1.45	-39	0.42	0.24	-0.65	63	-0.84
Other Financing Activities, net	-7.13	-0.58	4.53	-0.36	-1.45	-1.92	0.42	0.24	-0.65	-1.90	-0.44

This table presents ADMA Biologics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	489	329	348	276	208	127	89	108	24	24
Total Current Assets	331	257	270	209	154	86	45	62	22	21
Cash & Equivalents	103	51	87	51	56	27	23	43	9.91	10
Accounts Receivable	50	27	16	29	13	3.47	1.39	3.88	1.02	0.92
Inventories, net	170	173	163	125	82	53	19	13	5.02	3.45
Prepaid Expenses	8.03	5.33	5.10	4.34	3.05	2.53	1.77	1.23	0.31	0.11
Plant, Property, & Equipment, net	55	54	58	51	42	32	30	30	2.00	2.40
Total Noncurrent Assets	103	18	20	17	12	9.53	14	15	0.03	0.03
Goodwill	3.53	3.53	3.53	3.53	3.53	3.53	3.53	3.53	0.00	-
Intangible Assets	0.46	0.50	1.01	1.73	2.44	3.16	4.00	4.85	0.00	-
Noncurrent Deferred & Refundable Income Taxes	84	0.00	-	-	-	-	-	-	-	-
Other Noncurrent Operating Assets	14	14	15	11	6.37	2.84	6.70	6.83	0.03	0.03
Total Liabilities & Shareholders' Equity	489	329	348	276	208	127	89	108	24	24
Total Liabilities	140	194	196	135	119	101	69	68	28	23
Total Current Liabilities	56	50	39	30	20	14	9.63	9.44	11	4.22
Accounts Payable	20	16	13	12	11	9.17	5.90	5.92	2.56	2.09
Accrued Expenses	34	33	25	17	8.37	4.48	3.55	3.38	2.39	1.97
Current Deferred Revenue	0.14	0.18	0.14	0.14	0.14	0.14	0.14	0.14	0.15	0.15
Other Current Liabilities	1.22	1.05	0.91	0.59	0.37	0.23	-	-	0.02	-
Total Noncurrent Liabilities	84	144	157	105	99	87	59	58	17	19
Long-Term Debt	72	131	143	95	93	83	44	43	14	14
Capital Lease Obligations	8.56	9.78	11	7.46	4.33	1.30	0.12	0.00	-	0.04
Noncurrent Deferred Revenue	1.55	1.69	1.83	1.98	2.12	2.26	2.40	2.55	2.69	2.96
Other Noncurrent Operating Liabilities	1.67	2.11	1.85	0.40	0.05	0.11	13	13	0.12	1.43
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	349	135	152	141	88	26	20	40	-4.46	0.82
Total Preferred & Common Equity	349	135	152	141	88	26	20	40	-4.46	0.82
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-
Total Common Equity	349	135	152	141	88	26	20	40	-4.46	0.82
Common Stock	658	641	630	553	429	291	236	191	102	88
Retained Earnings	-309	-506	-478	-412	-340	-265	-216	-151	-107	-87

This table presents ADMA Biologics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	511	391	376	351	349	343	341	301
Total Current Assets	352	318	304	276	274	266	264	224
Cash & Equivalents	72	87	88	45	74	63	69	35
Accounts Receivable	99	50	30	50	31	37	27	21
Inventories, net	172	172	180	178	163	162	164	163
Prepaid Expenses	8.59	9.55	5.52	3.74	5.11	5.22	4.38	5.37
Plant, Property, & Equipment, net	58	54	54	55	55	56	57	57
Total Noncurrent Assets	101	19	18	19	20	20	19	20
Goodwill	3.53	3.53	3.53	3.53	3.53	3.53	3.53	3.53
Intangible Assets	0.45	0.49	0.48	0.32	0.48	0.66	0.83	1.19
Noncurrent Deferred & Refundable Income Taxes	81	-	-	-	-	-	-	-
Other Noncurrent Operating Assets	16	15	14	15	16	16	15	15
Total Liabilities & Shareholders' Equity	511	391	376	351	349	343	341	301
Total Liabilities	137	159	188	197	198	196	195	200
Total Current Liabilities	53	45	44	53	42	42	37	44
Accounts Payable	21	16	14	17	11	12	13	25
Accrued Expenses	32	28	28	34	30	29	23	18
Current Deferred Revenue	0.14	0.14	1.13	1.12	0.14	0.14	0.14	0.14
Other Current Liabilities	1.19	1.19	1.14	1.09	0.98	0.98	0.96	0.72
Total Noncurrent Liabilities	84	114	144	144	156	154	158	156
Long-Term Debt	73	101	131	131	142	140	144	141
Capital Lease Obligations	8.30	8.87	9.18	9.49	9.97	10	10	11
Noncurrent Deferred Revenue	1.51	1.58	1.62	1.65	1.73	1.76	1.80	1.87
Other Noncurrent Operating Liabilities	1.32	2.06	2.08	2.09	2.00	2.02	1.84	1.86
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	373	232	188	154	151	147	146	100
Total Preferred & Common Equity	373	232	188	154	151	147	146	100
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	373	232	188	154	151	147	146	100
Common Stock	655	652	645	642	640	638	630	566
Retained Earnings	-282	-420	-456	-488	-489	-491	-485	-466

This table displays calculated financial ratios and metrics derived from ADMA Biologics' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	65.15%	67.59%	90.36%	91.72%	43.85%	72.79%	-25.37%	113.49%	48.53%	21.34%
EBITDA Growth	359.55%	204.90%	40.38%	13.60%	-130.22%	53.88%	-55.63%	-120.49%	-10.96%	6.08%
EBIT Growth	550.22%	153.36%	31.77%	9.87%	-115.92%	50.14%	-53.65%	-126.94%	-12.17%	4.02%
NOPAT Growth	1,343.21%	154.95%	32.56%	10.08%	-56.71%	31.29%	-53.37%	-126.83%	-11.71%	3.15%
Net Income Growth	800.00%	57.15%	8.02%	5.41%	-56.90%	26.56%	-50.24%	-124.23%	-8.60%	-6.88%
EPS Growth	723.08%	60.61%	35.29%	42.05%	1.12%	38.62%	24.08%	-18.63%	6.94%	4.42%
Operating Cash Flow Growth	1,248.55%	114.79%	47.04%	-10.16%	-33.87%	-21.56%	-68.17%	-104.02%	-18.49%	-4.85%
Free Cash Flow Firm Growth	1,071.15%	118.30%	47.77%	-13.73%	-27.10%	-60.24%	31.95%	-360.41%	-39.00%	18.72%
Invested Capital Growth	45.73%	2.39%	13.81%	48.43%	54.43%	103.55%	6.57%	8,304.18%	127.25%	-53.06%
Revenue Q/Q Growth	11.40%	10.21%	18.09%	18.14%	4.76%	37.35%	-31.87%	0.12%	2.61%	171.82%
EBITDA Q/Q Growth	18.89%	188.84%	19.14%	7.76%	-17.64%	25.24%	-13.30%	-62.80%	14.20%	28.54%
EBIT Q/Q Growth	21.02%	2,879.15%	14.60%	6.35%	-16.68%	22.31%	-11.24%	-63.41%	13.11%	27.41%
NOPAT Q/Q Growth	90.21%	1,513.68%	15.34%	6.46%	-16.92%	17.39%	-11.06%	-63.37%	13.09%	27.22%
Net Income Q/Q Growth	190.13%	-23.71%	6.28%	3.71%	-13.22%	13.41%	-8.33%	-63.97%	11.14%	22.46%
EPS Q/Q Growth	189.29%	-30.00%	5.71%	20.31%	-3.53%	19.09%	-9.02%	4.02%	5.85%	-3.59%
Operating Cash Flow Q/Q Growth	37.91%	154.40%	30.48%	-1.12%	-14.05%	-1.14%	-9.49%	-35.40%	2.48%	-8.26%
Free Cash Flow Firm Q/Q Growth	30.64%	191.26%	37.99%	-9.64%	-16.37%	1.46%	-5.97%	-36.42%	4.85%	27.08%
Invested Capital Q/Q Growth	27.96%	-2.20%	0.69%	18.24%	15.87%	15.88%	18.59%	26.66%	157.13%	9.01%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	51.48%	34.44%	22.89%	1.45%	-45.17%	-34.60%	-148.42%	-28.14%	40.34%	39.93%
EBITDA Margin	34.62%	12.44%	-19.88%	-63.47%	-140.84%	-88.00%	-329.75%	-158.12%	-153.10%	-204.94%
Operating Margin	32.59%	8.38%	-25.55%	-72.12%	-153.75%	-141.14%	-354.95%	-172.71%	-162.56%	-216.14%
EBIT Margin	32.55%	8.27%	-25.96%	-72.43%	-154.06%	-102.64%	-355.70%	-172.76%	-162.52%	-215.20%
Profit (Net Income) Margin	46.35%	-10.94%	-42.77%	-88.52%	-179.41%	-164.50%	-387.06%	-192.26%	-183.05%	-250.36%
Tax Burden Percent	157.24%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	90.58%	-132.30%	164.76%	122.21%	116.46%	160.27%	108.82%	111.29%	112.64%	116.34%
Effective Tax Rate	-57.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	79.32%	6.83%	-13.40%	-25.38%	-42.55%	-46.33%	-105.59%	-140.55%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	16.83%	-48.77%	-78.25%	-91.85%	-103.70%	-95.01%	-342.99%	-1,130.62%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	2.32%	-26.50%	-31.57%	-37.08%	-89.83%	-163.75%	-113.18%	-103.40%	0.00%	0.00%
Return on Equity (ROE)	81.65%	-19.67%	-44.96%	-62.46%	-132.38%	-210.08%	-218.77%	-243.95%	1,073.36%	-526.23%
Cash Return on Invested Capital (CROIC)	42.10%	4.47%	-26.32%	-64.37%	-85.34%	-114.55%	-111.95%	-335.85%	-3,101.67%	0.00%
Operating Return on Assets (OROA)	33.94%	6.30%	-12.81%	-24.23%	-38.86%	-27.90%	-61.37%	-59.71%	-73.11%	-60.89%
Return on Assets (ROA)	48.34%	-8.33%	-21.10%	-29.61%	-45.25%	-44.71%	-66.78%	-66.45%	-82.34%	-70.83%
Return on Common Equity (ROCE)	81.65%	-19.67%	-44.96%	-62.46%	-132.38%	-210.08%	-218.77%	-243.94%	1,073.36%	-526.23%
Return on Equity Simple (ROE_SIMPLE)	56.64%	-20.89%	-43.37%	-50.75%	-85.83%	-184.32%	-332.53%	-108.49%	437.83%	-2,188.85%
Net Operating Profit after Tax (NOPAT)	219	15	-28	-41	-45	-29	-42	-28	-12	-11
NOPAT Margin	51.25%	5.86%	-17.88%	-50.48%	-107.63%	-98.80%	-248.46%	-120.90%	-113.79%	-151.30%
Net Nonoperating Expense Percent (NNEP)	62.49%	55.60%	64.86%	66.48%	61.15%	48.68%	237.40%	990.07%	613.49%	-147.78%
Return On Investment Capital (ROIC_SIMPLE)	50.83%	5.49%	-9.02%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	48.52%	65.56%	77.11%	98.55%	145.17%	134.60%	248.42%	128.14%	59.66%	60.07%
SG&A Expenses to Revenue	18.38%	24.51%	45.63%	68.18%	92.90%	95.68%	178.44%	110.96%	130.78%	158.33%
R&D to Revenue	0.43%	1.28%	2.35%	4.50%	13.99%	7.99%	23.11%	24.47%	72.12%	97.75%
Operating Expenses to Revenue	18.89%	26.07%	48.44%	73.57%	108.58%	106.54%	206.53%	144.58%	202.89%	256.07%
Earnings before Interest and Taxes (EBIT)	139	21	-40	-59	-65	-30	-60	-39	-17	-15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	148	32	-31	-51	-59	-26	-56	-36	-16	-15
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	11.62	7.55	5.02	1.96	2.09	9.06	5.60	2.05	0.00	105.31
Price to Tangible Book Value (P/TBV)	11.75	7.79	5.18	2.03	2.24	12.17	9.05	2.59	0.00	105.31
Price to Revenue (P/Rev)	9.51	3.96	4.96	3.41	4.37	8.08	6.52	3.64	6.19	12.05
Price to Earnings (P/E)	20.51	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	4.88%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	12.34	4.95	3.79	1.70	1.74	3.51	3.21	2.10	153.98	0.00
Enterprise Value to Revenue (EV/Rev)	9.45	4.30	5.39	4.04	5.35	10.05	7.79	3.57	6.65	11.70
Enterprise Value to EBITDA (EV/EBITDA)	27.31	34.56	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	29.05	52.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	18.45	73.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	33.97	126.18	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	34.76	112.11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.23	1.04	1.01	0.72	1.10	3.23	2.24	1.07	-4.54	17.42
Long-Term Debt to Equity	0.23	1.04	1.01	0.72	1.10	3.23	2.24	1.07	-3.17	17.40
Financial Leverage	0.14	0.54	0.40	0.40	0.87	1.72	0.33	0.09	-0.66	-1.41
Leverage Ratio	1.69	2.36	2.13	2.11	2.93	4.70	3.28	3.67	-13.04	7.43
Compound Leverage Factor	1.53	-3.12	3.51	2.58	3.41	7.53	3.56	4.09	-14.68	8.64
Debt to Total Capital	18.82%	50.94%	50.26%	42.02%	52.44%	76.34%	69.11%	51.58%	128.27%	94.57%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.05%	0.00%	38.76%	0.10%
Long-Term Debt to Total Capital	18.82%	50.94%	50.26%	42.02%	52.44%	76.34%	69.06%	51.58%	89.51%	94.47%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	81.18%	49.06%	49.74%	57.98%	47.56%	23.66%	30.89%	48.42%	-28.27%	5.43%
Debt to EBITDA	0.55	4.37	-5.01	-1.99	-1.64	-3.27	-0.79	-1.19	-1.24	-0.97
Net Debt to EBITDA	-0.15	2.77	-2.19	-1.00	-0.70	-2.24	-0.38	0.05	-0.30	0.17
Long-Term Debt to EBITDA	0.55	4.37	-5.01	-1.99	-1.64	-3.27	-0.79	-1.19	-0.86	-0.97
Debt to NOPAT	0.37	9.27	-5.57	-2.50	-2.14	-2.91	-1.05	-1.56	-1.67	-1.32
Net Debt to NOPAT	-0.10	5.88	-2.43	-1.25	-0.91	-1.99	-0.51	0.06	-0.41	0.23
Long-Term Debt to NOPAT	0.37	9.27	-5.57	-2.50	-2.14	-2.91	-1.05	-1.56	-1.16	-1.32
Altman Z-Score	19.02	2.76	1.27	-0.49	-1.43	-1.38	-4.03	-1.62	-6.35	-3.88
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.97	5.16	6.89	6.87	7.71	6.12	4.63	6.60	1.93	5.05
Quick Ratio	2.76	1.58	2.60	2.62	3.47	2.15	2.51	4.98	1.45	4.21
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	116	9.90	-54	-104	-91	-72	-45	-66	-14	-10
Operating Cash Flow to CapEx	1,442.65%	184.45%	-427.78%	-831.69%	-801.62%	-1,998.87%	-2,990.97%	-1,392.65%	-24,886.22%	-59,135.52%
Free Cash Flow to Firm to Interest Expense	7.64	0.19	-2.09	-7.94	-8.29	-3.78	-8.10	-14.62	-6.38	-4.01
Operating Cash Flow to Interest Expense	7.82	0.17	-2.29	-8.61	-9.28	-4.02	-11.35	-8.29	-8.16	-6.02
Operating Cash Flow Less CapEx to Interest Expense	7.28	0.08	-2.83	-9.64	-10.44	-4.22	-11.73	-8.89	-8.19	-6.03
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.04	0.76	0.49	0.33	0.25	0.27	0.17	0.35	0.45	0.28
Accounts Receivable Turnover	11.02	12.03	6.99	3.87	5.05	12.07	6.44	9.29	10.98	10.97
Inventory Turnover	1.21	1.01	0.83	0.77	0.91	1.10	2.70	3.31	1.50	1.67
Fixed Asset Turnover	7.86	4.61	2.82	1.75	1.15	0.95	0.56	1.40	4.85	2.74
Accounts Payable Turnover	11.53	11.72	9.26	6.79	6.05	5.24	7.14	6.87	2.73	2.23
Days Sales Outstanding (DSO)	33.13	30.34	52.21	94.28	72.22	30.24	56.65	39.27	33.25	33.27
Days Inventory Outstanding (DIO)	302.67	362.46	442.37	471.89	400.78	331.15	135.14	110.44	242.90	218.19
Days Payable Outstanding (DPO)	31.65	31.15	39.41	53.77	60.29	69.64	51.13	53.10	133.49	163.69
Cash Conversion Cycle (CCC)	304.16	361.65	455.18	512.39	412.71	291.74	140.66	96.61	142.66	87.77
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	327	224	219	192	130	84	41	39	0.46	-1.69
Invested Capital Turnover	1.55	1.17	0.75	0.50	0.40	0.47	0.43	1.16	-17.35	-5.14
Increase / (Decrease) in Invested Capital	103	5.24	27	63	46	43	2.54	38	2.15	-0.59
Enterprise Value (EV)	4,032	1,110	831	327	226	295	132	81	71	84
Market Capitalization	4,054	1,021	763	276	184	237	111	83	66	86
Book Value per Share	$1.48	$0.60	$0.77	$0.72	$0.93	$0.44	$0.43	$1.56	($0.35)	$0.08
Tangible Book Value per Share	$1.46	$0.58	$0.75	$0.69	$0.87	$0.33	$0.26	$1.24	($0.35)	$0.08
Total Capital	430	276	306	244	186	111	64	83	16	15
Total Debt	81	140	154	102	97	85	44	43	20	14
Total Long-Term Debt	81	140	154	102	97	85	44	43	14	14
Net Debt	-22	89	67	51	41	58	21	-1.64	4.92	-2.51
Capital Expenditures (CapEx)	8.23	4.77	14	14	13	3.81	2.10	2.68	0.07	0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)	173	156	145	127	78	45	12	8.29	1.24	0.28
Debt-free Net Working Capital (DFNWC)	276	207	231	178	134	72	35	53	17	17
Net Working Capital (NWC)	276	207	231	178	134	72	35	53	10	17
Net Nonoperating Expense (NNE)	21	43	38	31	30	19	24	16	7.38	7.11
Net Nonoperating Obligations (NNO)	-22	89	67	51	41	58	21	-1.64	4.92	-2.51
Total Depreciation and Amortization (D&A)	8.85	11	9.37	7.25	5.58	4.30	4.41	3.33	1.00	0.74
Debt-free, Cash-free Net Working Capital to Revenue	40.50%	60.36%	93.86%	157.22%	184.44%	153.46%	71.71%	36.44%	11.63%	3.90%
Debt-free Net Working Capital to Revenue	64.69%	80.25%	150.01%	220.34%	316.90%	244.62%	205.68%	232.43%	155.19%	238.09%
Net Working Capital to Revenue	64.69%	80.25%	150.01%	220.34%	316.90%	244.62%	205.50%	232.43%	97.87%	237.88%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.85	($0.13)	($0.33)	($0.51)	($0.88)	($0.89)	($1.45)	($1.91)	($1.61)	($1.73)
Adjusted Weighted Average Basic Shares Outstanding	233.08M	223.98M	197.87M	139.58M	121.28M	86.35M	46.35M	45.32M	12.89M	10.71M
Adjusted Diluted Earnings per Share	$0.81	($0.13)	($0.33)	($0.51)	($0.88)	($0.89)	($1.45)	($1.91)	($1.61)	($1.73)
Adjusted Weighted Average Diluted Shares Outstanding	243.34M	223.98M	197.87M	139.58M	121.28M	86.35M	46.35M	45.32M	12.89M	10.71M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($0.88)	($0.89)	($1.45)	($1.91)	($1.61)	($1.73)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	237.62M	228.22M	222.16M	195.92M	86.15M	54.35M	45.19M	22.90M	12.15M	10.41M
Normalized Net Operating Profit after Tax (NOPAT)	97	15	-28	-41	-45	-29	-42	-27	-12	-11
Normalized NOPAT Margin	22.81%	5.86%	-17.88%	-50.48%	-107.63%	-98.80%	-248.46%	-118.30%	-113.79%	-151.30%
Pre Tax Income Margin	29.48%	-10.94%	-42.77%	-88.52%	-179.41%	-164.50%	-387.06%	-192.26%	-183.05%	-250.36%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	9.15	0.42	-1.54	-4.49	-5.92	-1.59	-10.94	-8.75	-7.74	-6.03
NOPAT to Interest Expense	14.40	0.30	-1.06	-3.13	-4.13	-1.53	-7.64	-6.12	-5.42	-4.24
EBIT Less CapEx to Interest Expense	8.61	0.32	-2.08	-5.52	-7.07	-1.79	-11.32	-9.34	-7.77	-6.04
NOPAT Less CapEx to Interest Expense	13.86	0.20	-1.60	-4.16	-5.29	-1.73	-8.02	-6.72	-5.45	-4.25
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from ADMA Biologics' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	40.22%	59.06%	78.13%	78.29%	43.86%	47.86%	63.73%	77.33%	95.56%	89.45%	98.69%
EBITDA Growth	53.17%	138.81%	268.81%	1,729.68%	1,366.08%	511.94%	273.60%	131.61%	112.81%	63.85%	48.04%
EBIT Growth	59.81%	170.59%	363.49%	8,162.76%	2,693.57%	317.48%	191.57%	94.71%	94.39%	51.28%	35.32%
NOPAT Growth	32.86%	1,139.90%	345.96%	10,688.33%	3,810.32%	334.93%	233.17%	94.84%	94.51%	54.07%	35.47%
Net Income Growth	51.10%	734.19%	1,299.96%	603.25%	362.28%	-44.25%	117.22%	53.72%	72.85%	26.54%	15.88%
EPS Growth	37.50%	662.50%	1,400.00%	533.33%	366.67%	-60.00%	112.50%	57.14%	76.92%	28.57%	38.46%
Operating Cash Flow Growth	-787.06%	185.37%	108.83%	853.36%	84.94%	338.47%	190.22%	52.78%	43.40%	77.95%	0.95%
Free Cash Flow Firm Growth	-3,024.08%	344.24%	506.62%	231.69%	112.63%	115.33%	94.93%	59.94%	54.62%	57.21%	-0.51%
Invested Capital Growth	53.84%	45.73%	11.39%	2.34%	7.57%	2.39%	5.42%	10.40%	13.83%	13.81%	33.64%
Revenue Q/Q Growth	-2.34%	-1.91%	11.80%	30.92%	10.79%	9.85%	11.90%	5.64%	13.87%	21.64%	21.19%
EBITDA Q/Q Growth	-8.48%	-3.29%	0.76%	71.76%	42.68%	49.35%	399.87%	37.63%	140.09%	37.06%	9.00%
EBIT Q/Q Growth	-8.94%	-3.40%	1.01%	79.86%	54.16%	65.47%	1,857.20%	42.14%	87.07%	30.33%	-1.44%
NOPAT Q/Q Growth	-77.29%	218.94%	10.48%	66.03%	111.94%	14.72%	2,723.07%	41.82%	86.58%	34.97%	-1.55%
Net Income Q/Q Growth	-75.96%	211.61%	12.00%	80.06%	200.92%	-787.88%	140.26%	6.16%	44.50%	17.91%	-8.24%
EPS Q/Q Growth	-75.56%	200.00%	15.38%	62.50%	200.00%	-900.00%	133.33%	0.00%	40.00%	37.50%	-14.29%
Operating Cash Flow Q/Q Growth	-139.18%	100.64%	-45.17%	2,157.98%	-112.61%	46.83%	297.80%	58.85%	-99.52%	44.45%	-3.54%
Free Cash Flow Firm Q/Q Growth	-604.27%	66.21%	-57.28%	716.60%	-23.39%	252.13%	86.16%	21.66%	7.02%	49.70%	-9.35%
Invested Capital Q/Q Growth	17.09%	27.96%	6.28%	-3.39%	10.92%	-2.20%	-2.35%	1.54%	5.59%	0.69%	2.26%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	53.22%	53.88%	49.78%	53.60%	47.77%	42.06%	36.65%	27.76%	29.01%	28.36%	23.50%
EBITDA Margin	32.18%	34.34%	34.83%	38.65%	29.46%	22.87%	16.82%	3.77%	2.89%	-8.21%	-15.87%
Operating Margin	30.38%	32.60%	33.08%	36.57%	26.65%	19.26%	12.91%	-0.79%	-1.43%	-12.12%	-22.67%
EBIT Margin	30.33%	32.53%	33.03%	36.56%	26.61%	19.12%	12.69%	-0.81%	-1.48%	-13.00%	-22.70%
Profit (Net Income) Margin	23.44%	95.19%	29.96%	29.91%	21.75%	-23.87%	3.81%	-10.60%	-11.93%	-24.47%	-36.26%
Tax Burden Percent	80.43%	322.35%	97.71%	89.43%	96.77%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	96.07%	90.78%	92.84%	91.49%	84.46%	-124.86%	30.04%	1,310.91%	808.21%	188.25%	159.76%
Effective Tax Rate	19.57%	-222.35%	2.29%	10.57%	3.23%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	35.56%	162.67%	51.06%	45.47%	30.43%	15.71%	13.54%	-0.51%	-0.84%	-6.36%	-10.89%
ROIC Less NNEP Spread (ROIC-NNEP)	33.35%	127.82%	45.48%	41.19%	26.77%	-19.68%	7.26%	-7.00%	-8.53%	-19.87%	-20.36%
Return on Net Nonoperating Assets (RNNOA)	6.59%	17.63%	12.02%	17.22%	16.15%	-10.69%	5.62%	-4.99%	-5.06%	-8.02%	-17.74%
Return on Equity (ROE)	42.16%	180.30%	63.08%	62.69%	46.58%	5.02%	19.16%	-5.50%	-5.90%	-14.37%	-28.63%
Cash Return on Invested Capital (CROIC)	28.33%	42.10%	36.64%	33.02%	5.62%	4.47%	-4.86%	-15.10%	-21.11%	-26.32%	-45.92%
Operating Return on Assets (OROA)	32.35%	33.92%	34.19%	33.56%	21.79%	14.57%	9.16%	-0.53%	-0.83%	-6.41%	-10.99%
Return on Assets (ROA)	24.99%	99.27%	31.02%	27.46%	17.81%	-18.19%	2.75%	-6.89%	-6.69%	-12.07%	-17.55%
Return on Common Equity (ROCE)	42.16%	180.30%	63.08%	62.69%	46.58%	5.02%	19.16%	-5.50%	-5.90%	-14.37%	-28.63%
Return on Equity Simple (ROE_SIMPLE)	55.37%	0.00%	29.38%	18.48%	-2.37%	0.00%	-15.07%	-27.45%	-32.74%	0.00%	-70.05%
Net Operating Profit after Tax (NOPAT)	28	124	39	35	21	9.96	8.69	-0.33	-0.57	-4.24	-6.52
NOPAT Margin	24.44%	105.09%	32.32%	32.71%	25.79%	13.48%	12.91%	-0.55%	-1.00%	-8.48%	-15.87%
Net Nonoperating Expense Percent (NNEP)	2.21%	34.86%	5.57%	4.28%	3.67%	35.39%	6.28%	6.48%	7.69%	13.51%	9.46%
Return On Investment Capital (ROIC_SIMPLE)	6.18%	28.73%	-	-	-	3.62%	-	-	-	-1.39%	-
Cost of Revenue to Revenue	46.78%	46.12%	50.22%	46.40%	52.23%	57.94%	63.35%	72.24%	70.99%	71.64%	76.50%
SG&A Expenses to Revenue	22.09%	20.92%	16.34%	16.37%	20.33%	21.95%	22.58%	25.92%	28.63%	37.98%	43.20%
R&D to Revenue	0.72%	0.33%	0.34%	0.52%	0.55%	0.60%	0.89%	2.33%	1.50%	2.15%	2.54%
Operating Expenses to Revenue	22.84%	21.28%	16.71%	17.03%	21.11%	22.80%	23.74%	28.55%	30.44%	40.49%	46.18%
Earnings before Interest and Taxes (EBIT)	35	38	40	39	22	14	8.54	-0.49	-0.84	-6.50	-9.33
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	37	40	42	41	24	17	11	2.26	1.65	-4.10	-6.52
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	12.62	11.62	20.09	13.77	9.70	7.55	5.32	5.59	5.05	5.02	4.75
Price to Tangible Book Value (P/TBV)	12.76	11.75	20.45	14.07	9.95	7.79	5.46	5.75	5.20	5.18	4.99
Price to Revenue (P/Rev)	10.26	9.51	12.17	7.85	5.27	3.96	3.44	3.94	4.04	4.96	3.66
Price to Earnings (P/E)	22.80	20.51	68.39	74.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	4.39%	4.88%	1.46%	1.34%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	12.35	12.34	18.34	11.00	6.38	4.95	3.85	3.87	3.55	3.79	2.73
Enterprise Value to Revenue (EV/Rev)	10.28	9.45	12.23	8.01	5.60	4.30	3.77	4.36	4.51	5.39	4.55
Enterprise Value to EBITDA (EV/EBITDA)	29.44	27.31	37.71	28.20	29.05	34.56	79.39	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	31.11	29.05	40.83	31.61	36.08	52.02	1,232.41	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	21.15	18.45	40.76	31.49	51.20	73.33	940.99	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	46.67	33.97	54.42	36.21	74.46	126.18	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	52.81	34.76	52.74	33.70	117.59	112.11	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.22	0.23	0.48	0.75	0.91	1.04	1.00	1.03	1.06	1.01	1.51
Long-Term Debt to Equity	0.22	0.23	0.48	0.75	0.91	1.04	1.00	1.03	1.06	1.01	1.51
Financial Leverage	0.20	0.14	0.26	0.42	0.60	0.54	0.77	0.71	0.59	0.40	0.87
Leverage Ratio	1.63	1.69	1.93	2.15	2.31	2.36	2.58	2.45	2.38	2.13	2.65
Compound Leverage Factor	1.57	1.53	1.79	1.96	1.95	-2.95	0.77	32.12	19.24	4.01	4.24
Debt to Total Capital	17.79%	18.82%	32.21%	42.69%	47.73%	50.94%	50.09%	50.63%	51.52%	50.26%	60.23%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	17.79%	18.82%	32.21%	42.69%	47.73%	50.94%	50.09%	50.63%	51.52%	50.26%	60.23%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	82.21%	81.18%	67.79%	57.31%	52.27%	49.06%	49.91%	49.37%	48.48%	49.74%	39.77%
Debt to EBITDA	0.50	0.55	0.89	1.50	2.57	4.37	13.66	-22.42	-9.59	-5.01	-4.01
Net Debt to EBITDA	0.06	-0.15	0.19	0.55	1.74	2.77	7.00	-13.11	-5.30	-2.19	-3.09
Long-Term Debt to EBITDA	0.50	0.55	0.89	1.50	2.57	4.37	13.66	-22.42	-9.59	-5.01	-4.01
Debt to NOPAT	0.36	0.37	0.96	1.67	4.53	9.27	161.97	-12.91	-8.72	-5.57	-4.67
Net Debt to NOPAT	0.04	-0.10	0.20	0.62	3.07	5.88	82.95	-7.55	-4.82	-2.43	-3.60
Long-Term Debt to NOPAT	0.36	0.37	0.96	1.67	4.53	9.27	161.97	-12.91	-8.72	-5.57	-4.67
Altman Z-Score	21.68	18.34	18.26	8.62	4.37	2.69	2.03	1.89	1.60	1.59	0.31
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.58	5.97	7.09	6.87	5.21	5.16	6.54	6.35	7.19	6.89	5.04
Quick Ratio	3.20	2.76	3.05	2.68	1.79	1.58	2.52	2.37	2.61	2.60	1.26
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-106	21	13	30	3.62	4.73	-3.11	-22	-29	-31	-61
Operating Cash Flow to CapEx	-418.53%	1,821.40%	2,370.08%	2,209.39%	-94.50%	1,470.09%	1,583.22%	-694.84%	-756.97%	-196.86%	-392.98%
Free Cash Flow to Firm to Interest Expense	-53.59	5.09	3.61	7.81	0.96	0.15	-0.49	-3.56	-4.69	-5.37	-10.98
Operating Cash Flow to Interest Expense	-9.96	12.18	7.15	12.07	-0.59	0.54	1.87	-0.96	-2.41	-1.29	-2.38
Operating Cash Flow Less CapEx to Interest Expense	-12.34	11.51	6.85	11.52	-1.21	0.51	1.75	-1.10	-2.73	-1.94	-2.99
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.07	1.04	1.04	0.92	0.82	0.76	0.72	0.65	0.56	0.49	0.48
Accounts Receivable Turnover	6.16	11.02	9.40	9.88	7.44	12.03	8.97	7.48	6.98	6.99	6.32
Inventory Turnover	1.25	1.21	1.17	1.04	1.00	1.01	1.00	0.98	0.88	0.83	0.76
Fixed Asset Turnover	8.13	7.86	7.06	5.97	5.03	4.61	4.19	3.74	3.29	2.82	2.48
Accounts Payable Turnover	11.53	11.53	14.55	13.55	11.39	11.72	9.00	12.87	9.88	9.26	4.99
Days Sales Outstanding (DSO)	59.21	33.13	38.83	36.94	49.07	30.34	40.68	48.77	52.32	52.21	57.76
Days Inventory Outstanding (DIO)	293.15	302.67	312.64	350.34	363.34	362.46	366.70	371.90	413.54	442.37	477.50
Days Payable Outstanding (DPO)	31.66	31.65	25.08	26.94	32.05	31.15	40.55	28.36	36.93	39.41	73.22
Cash Conversion Cycle (CCC)	320.70	304.16	326.39	360.34	380.36	361.65	366.83	392.32	428.93	455.18	462.04
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	383	327	255	240	249	224	229	235	231	219	217
Invested Capital Turnover	1.46	1.55	1.58	1.39	1.18	1.17	1.05	0.93	0.84	0.75	0.69
Increase / (Decrease) in Invested Capital	134	103	26	5.50	17	5.24	12	22	28	27	55
Enterprise Value (EV)	4,723	4,032	4,683	2,644	1,586	1,110	883	908	821	831	594
Market Capitalization	4,714	4,054	4,659	2,592	1,491	1,021	805	820	735	763	477
Book Value per Share	$1.57	$1.48	$0.99	$0.81	$0.67	$0.60	$0.67	$0.66	$0.66	$0.77	$0.51
Tangible Book Value per Share	$1.55	$1.46	$0.98	$0.79	$0.65	$0.58	$0.66	$0.64	$0.64	$0.75	$0.49
Total Capital	454	430	342	329	294	276	303	297	300	306	252
Total Debt	81	81	110	140	140	140	152	151	155	154	152
Total Long-Term Debt	81	81	110	140	140	140	152	151	155	154	152
Net Debt	9.20	-22	23	52	95	89	78	88	86	67	117
Capital Expenditures (CapEx)	4.70	2.76	1.06	2.07	2.35	1.20	0.76	0.87	1.95	3.75	3.38
Debt-free, Cash-free Net Working Capital (DFCFNWC)	227	173	187	171	178	156	158	162	158	145	145
Debt-free Net Working Capital (DFNWC)	298	276	273	260	223	207	232	224	227	231	180
Net Working Capital (NWC)	298	276	273	260	223	207	232	224	227	231	180
Net Nonoperating Expense (NNE)	1.15	12	2.82	3.00	3.31	28	6.12	6.04	6.22	7.99	8.38
Net Nonoperating Obligations (NNO)	9.20	-22	23	52	95	89	78	88	86	67	117
Total Depreciation and Amortization (D&A)	2.12	2.13	2.16	2.24	2.33	2.77	2.78	2.75	2.49	2.39	2.81
Debt-free, Cash-free Net Working Capital to Revenue	49.35%	40.50%	48.74%	51.86%	62.86%	60.36%	67.31%	77.74%	86.95%	93.86%	110.93%
Debt-free Net Working Capital to Revenue	64.94%	64.69%	71.39%	78.58%	78.87%	80.25%	98.96%	107.78%	125.00%	150.01%	137.69%
Net Working Capital to Revenue	64.94%	64.69%	71.39%	78.58%	78.87%	80.25%	98.96%	107.78%	125.00%	150.01%	137.69%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.11	$0.48	$0.15	$0.14	$0.08	($0.08)	$0.01	($0.03)	($0.03)	($0.05)	($0.08)
Adjusted Weighted Average Basic Shares Outstanding	237.78M	233.08M	234.57M	232.42M	228.87M	223.98M	225.28M	222.68M	221.92M	197.87M	196.38M
Adjusted Diluted Earnings per Share	$0.11	$0.45	$0.15	$0.13	$0.08	($0.08)	$0.01	($0.03)	($0.03)	($0.05)	($0.08)
Adjusted Weighted Average Diluted Shares Outstanding	244.68M	243.34M	244.80M	242.17M	236.41M	223.98M	233.76M	222.68M	221.92M	197.87M	196.38M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	237.62M	236.39M	233.08M	231.81M	228.22M	225.97M	224.91M	222.27M	222.16M	196.78M
Normalized Net Operating Profit after Tax (NOPAT)	28	27	39	35	21	9.96	6.08	-0.33	-0.57	-4.24	-6.52
Normalized NOPAT Margin	24.44%	22.82%	32.32%	32.71%	25.79%	13.48%	9.04%	-0.55%	-1.00%	-8.48%	-15.87%
Pre Tax Income Margin	29.14%	29.53%	30.67%	33.45%	22.47%	-23.87%	3.81%	-10.60%	-11.93%	-24.47%	-36.26%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	17.63	9.28	11.31	10.36	5.78	0.44	1.33	-0.08	-0.14	-1.13	-1.67
NOPAT to Interest Expense	14.21	29.97	11.07	9.27	5.60	0.31	1.36	-0.05	-0.09	-0.74	-1.17
EBIT Less CapEx to Interest Expense	15.25	8.61	11.01	9.81	5.16	0.40	1.22	-0.22	-0.46	-1.79	-2.28
NOPAT Less CapEx to Interest Expense	11.82	29.30	10.77	8.72	4.98	0.27	1.24	-0.19	-0.41	-1.39	-1.77
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About ADMA Biologics' Financials

When does ADMA Biologics's fiscal year end?

According to the most recent income statement we have on file, ADMA Biologics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has ADMA Biologics' net income changed over the last 9 years?

ADMA Biologics' net income appears to be on a downward trend, with a most recent value of $197.67 million in 2024, falling from -$17.97 million in 2015. The previous period was -$28.24 million in 2023. View ADMA Biologics' forecast to see where analysts expect ADMA Biologics to go next.

What is ADMA Biologics's operating income?

ADMA Biologics's total operating income in 2024 was $138.98 million, based on the following breakdown:

Total Gross Profit: $219.55 million
Total Operating Expenses: $80.57 million

How has ADMA Biologics revenue changed over the last 9 years?

Over the last 9 years, ADMA Biologics' total revenue changed from $7.18 million in 2015 to $426.45 million in 2024, a change of 5,841.4%.

How much debt does ADMA Biologics have?

ADMA Biologics' total liabilities were at $139.66 million at the end of 2024, a 28.0% decrease from 2023, and a 510.0% increase since 2015.

How much cash does ADMA Biologics have?

In the past 9 years, ADMA Biologics' cash and equivalents has ranged from $9.91 million in 2016 to $103.15 million in 2024, and is currently $103.15 million as of their latest financial filing in 2024.

How has ADMA Biologics' book value per share changed over the last 9 years?

Over the last 9 years, ADMA Biologics' book value per share changed from 0.08 in 2015 to 1.48 in 2024, a change of 1,827.4%.

Related Companies

This page (NASDAQ:ADMA) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ADMA Biologics (ADMA) Financials

Frequently Asked Questions About ADMA Biologics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ADMA Biologics (ADMA) Financials

Annual Income Statements for ADMA Biologics

Quarterly Income Statements for ADMA Biologics

Annual Cash Flow Statements for ADMA Biologics

Quarterly Cash Flow Statements for ADMA Biologics

Annual Balance Sheets for ADMA Biologics

Quarterly Balance Sheets for ADMA Biologics

Annual Metrics And Ratios for ADMA Biologics

Quarterly Metrics And Ratios for ADMA Biologics

Frequently Asked Questions About ADMA Biologics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools